14. Prior chemotherapy, radiotherapy, immunotherapy or investigational therapy (including Chinese herbal medicine and Chinese patent medicine) used to control cancer including locoregional treatment must have been completed ≥ 4 weeks before the first dose of BGB-A317, and all treatment-related adverse events (except alopecia) are stable and have either returned to baseline or Grade 0/1.